HIV infection: epidemiology, pathogenesis, treatment, and prevention (Q34662270)

3 August 2017

HIV infection: epidemiology, pathogenesis, treatment, and prevention (English)

1 reference

3 August 2017

0 references

0 references

prevention of HIV/AIDS

0 references

1 reference

1 reference

2

Connie Celum

1 reference

3 August 2017

Gary Maartens

1

0 references

Sharon R. Lewin

object named as

Sharon R Lewin

series ordinal

3

0 references

language of work or name

English

0 references

publication date

5 June 2014

1 reference

3 August 2017

1 reference

3 August 2017

384

1 reference

3 August 2017

258-271

1 reference

3 August 2017

9939

1 reference

Origins of HIV and the AIDS pandemic

3 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Global trends in molecular epidemiology of HIV-1 during 2000-2007.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Dramatic increase in HIV prevalence after scale-up of antiretroviral treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

HIV incidence in men who have sex with men in England and Wales 2001-10: a nationwide population study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Past as prologue: the refractory and evolving HIV epidemic among men who have sex with men

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

The increase in global HIV epidemics in MSM.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

The burden of HIV: insights from the Global Burden of Disease Study 2010

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

HIV infection and the risk of acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Increasing burden of liver disease in patients with HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Global epidemiology of tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

CD4 Decline and Incidence of Opportunistic Infections in Cape Town, South Africa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

The prevalence and drug sensitivity of tuberculosis among patients dying in hospital in KwaZulu-Natal, South Africa: a postmortem study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Acute HIV-1 Infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Estimating the impact of plasma HIV-1 RNA reductions on heterosexual HIV-1 transmission risk

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

A systematic review of the epidemiologic interactions between classic sexually transmitted diseases and HIV: how much really is known?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Herpes simplex virus type 2: a key role in HIV incidence

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Bacterial vaginosis and HIV acquisition: a meta-analysis of published studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Increased risk of HIV-1 transmission in pregnancy: a prospective study among African HIV-1-serodiscordant couples

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

HIV transmission risk through anal intercourse: systematic review, meta-analysis and implications for HIV prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Male circumcision and risk of HIV infection in sub-Saharan Africa: a systematic review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Use of hormonal contraceptives and HIV acquisition in women: a systematic review of the epidemiological evidence.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Modelling the global competing risks of a potential interaction between injectable hormonal contraception and HIV risk

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Effect of concurrent sexual partnerships on rate of new HIV infections in a high-prevalence, rural South African population: a cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Concurrent partnerships and HIV: an inconvenient truth

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Determinants of per-coital-act HIV-1 infectivity among African HIV-1-serodiscordant couples

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Progress in HIV reduction and prevention among injection and noninjection drug users

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Intimate partner violence, relationship power inequity, and incidence of HIV infection in young women in South Africa: a cohort study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

CD4-independent infection of astrocytes by human immunodeficiency virus type 1: requirement for the human mannose receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Virological synapses allow HIV-1 uptake and gene expression in renal tubular epithelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

The cytosolic exonuclease TREX1 inhibits the innate immune response to human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

LEDGF/p75 is essential for nuclear and chromosomal targeting of HIV-1 integrase in human cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Phenotypic properties of transmitted founder HIV-1

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Induction of a Striking Systemic Cytokine Cascade prior to Peak Viremia in Acute Human Immunodeficiency Virus Type 1 Infection, in Contrast to More Modest and Delayed Responses in Acute Hepatitis B and C Virus Infections

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

A molecular basis for the control of preimmune escape variants by HIV-specific CD8+ T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Rapid evolution of the neutralizing antibody response to HIV type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Broad neutralization coverage of HIV by multiple highly potent antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Somatic Mutations of the Immunoglobulin Framework Are Generally Required for Broad and Potent HIV-1 Neutralization

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Rational HIV Immunogen Design to Target Specific Germline B Cell Receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

HIV-1 adaptation to NK-cell-mediated immune pressure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

HIV-1 causes CD4 cell death through DNA-dependent protein kinase during viral integration.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Mechanisms of gastrointestinal CD4+ T-cell depletion during acute and early human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

HIV-1 infection is characterized by profound depletion of CD161+ Th17 cells and gradual decline in regulatory T cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Early and nonreversible decrease of CD161++ /MAIT cells in HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Microbial translocation is a cause of systemic immune activation in chronic HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Lymphoid tissue damage in HIV-1 infection depletes naïve T cells and limits T cell reconstitution after antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Biomarkers of immune dysfunction following combination antiretroviral therapy for HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Sex differences in the Toll-like receptor-mediated response of plasmacytoid dendritic cells to HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell responses

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Inflammatory and coagulation biomarkers and mortality in patients with HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Carotid Intima-Media Thickness Progression in HIV-Infected Adults Occurs Preferentially at the Carotid Bifurcation and Is Predicted by Inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Markers of microbial translocation and risk of AIDS-related lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Biomarkers of inflammation and coagulation are associated with mortality and hepatitis flares in persons coinfected with HIV and hepatitis viruses

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

High levels of chronic immune activation in the T-cell compartments of patients coinfected with hepatitis C virus and human immunodeficiency virus type 1 and on highly active antiretroviral therapy are reverted by alpha interferon and ribavirin trea

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Persistent immune activation in chronic HIV infection: do any interventions work?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Discordant responses to potent antiretroviral treatment in previously naive HIV-1-infected adults initiating treatment in resource-constrained countries: the antiretroviral therapy in low-income countries (ART-LINC) collaboration

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Clinical predictors of immune reconstitution following combination antiretroviral therapy in patients from the Australian HIV Observational Database

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Causes of death among Danish HIV patients compared with population controls in the period 1995-2008.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Interleukin-2 therapy in patients with HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Interleukin-7 promotes HIV persistence during antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Monitoring of HIV viral load, CD4 cell count, and clinical assessment versus clinical monitoring alone for antiretroviral therapy in low-resource settings (Stratall ANRS 12110/ESTHER): a cost-effectiveness analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Public-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland compared

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Antiretroviral therapy in early HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Rating evidence in treatment guidelines: a case example of when to initiate combination antiretroviral therapy (cART) in HIV-positive asymptomatic persons

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Clinical uncertainties, health service challenges, and ethical complexities of HIV "test-and-treat": a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Quantifying and addressing losses along the continuum of care for people living with HIV infection in sub-Saharan Africa: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Antiretroviral medication adherence and the development of class-specific antiretroviral resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Pathogenesis and prevention of immune reconstitution disease during antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Higher CNS Penetration-Effectiveness of Long-term Combination Antiretroviral Therapy Is Associated With Better HIV-1 Viral Suppression in Cerebrospinal Fluid

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

CCR7 ligands CCL19 and CCL21 increase permissiveness of resting memory CD4+ T cells to HIV-1 infection: a novel model of HIV-1 latency.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Both CD31(+) and CD31⁻ naive CD4(+) T cells are persistent HIV type 1-infected reservoirs in individuals receiving antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Restricted HIV-1 infection of human astrocytes: potential role of nef in the regulation of virus replication.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

HIV-1 transcription and latency: an update

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Cellular microRNAs contribute to HIV-1 latency in resting primary CD4+ T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Absence of detectable HIV-1 viremia after treatment cessation in an infant

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Genomic editing of the HIV-1 coreceptor CCR5 in adult hematopoietic stem and progenitor cells using zinc finger nucleases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Impact of multi-targeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

HIV cure and eradication: how will we get from the laboratory to effective clinical trials?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Comprehensive analysis of virus-specific T-cells provides clues for the failure of therapeutic immunization with ALVAC-HIV vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

A dendritic cell-based vaccine elicits T cell responses associated with control of HIV-1 replication

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Immune clearance of highly pathogenic SIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Key harm reduction interventions and their impact on the reduction of risky behavior and HIV incidence among people who inject drugs in low-income and middle-income countries.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Mother-to-child transmission of HIV-1: timing and implications for prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Late postnatal transmission of HIV-1 in breast-fed children: an individual patient data meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana: a randomized trial: the Mashi Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Efficacy and safety of an extended nevirapine regimen in infant children of breastfeeding mothers with HIV-1 infection for prevention of postnatal HIV-1 transmission (HPTN 046): a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Triple-antiretroviral prophylaxis to prevent mother-to-child HIV transmission through breastfeeding--the Kisumu Breastfeeding Study, Kenya: a clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Missed opportunities to prevent mother-to-child-transmission: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Adherence to antiretroviral therapy during and after pregnancy in low-income, middle-income, and high-income countries: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Prevention of HIV-1 infection with early antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Uptake of home-based voluntary HIV testing in sub-Saharan Africa: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Test-and-treat in Los Angeles: a mathematical model of the effects of test-and-treat for the population of men who have sex with men in Los Angeles County.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Antiretroviral prophylaxis for HIV prevention in heterosexual men and women

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Preexposure chemoprophylaxis for HIV prevention in men who have sex with men

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Preexposure prophylaxis for HIV infection among African women

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Vaginal microbicides for reducing the risk of sexual acquisition of HIV infection in women: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Drug-eluting fibers for HIV-1 inhibition and contraception

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Male circumcision for prevention of heterosexual acquisition of HIV in men

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Will circumcision provide even more protection from HIV to women and men? New estimates of the population impact of circumcision interventions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

The cost-utility analysis of adult male circumcision for prevention of heterosexual acquisition of HIV in men in sub-Saharan Africa: a probabilistic decision model

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Safety of task-shifting for male medical circumcision: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Programme science research on medical male circumcision scale-up in sub-Saharan Africa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Systematic review of reviews of behavioural HIV prevention interventions among men who have sex with men.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Behavioral interventions to reduce the transmission of HIV infection among sex workers and their clients in low- and middle-income countries

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Community empowerment among female sex workers is an effective HIV prevention intervention: a systematic review of the peer-reviewed evidence from low- and middle-income countries

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Behavioural interventions for HIV positive prevention in developing countries: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Efficacy of behavioral interventions to increase condom use and reduce sexually transmitted infections: a meta-analysis, 1991 to 2010.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Voluntary counseling and testing (VCT) for changing HIV-related risk behavior in developing countries

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Infectious co-factors in HIV-1 transmission herpes simplex virus type-2 and HIV-1: new insights and interventions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

High-dose valacyclovir HSV-2 suppression results in greater reduction in plasma HIV-1 levels compared with standard dose acyclovir among HIV-1/HSV-2 coinfected persons: a randomized, crossover trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

The role of coinfections in HIV epidemic trajectory and positive prevention: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Population-based biomedical sexually transmitted infection control interventions for reducing HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

Immune-correlates analysis of an HIV-1 vaccine efficacy trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960164-1

7 January 2021

10.1016/S0140-6736(14)60164-1

Identifiers

DOI

1 reference

3 August 2017

1 reference

PubMed ID

24907868